Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:KALV NASDAQ:KROS NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$11.22-6.5%$18.72$8.04▼$24.17$325.85M2.391.93 million shs3.86 million shsKALVKalVista Pharmaceuticals$11.13+1.2%$12.84$7.30▼$17.28$555.75M-0.151.27 million shs1.22 million shsKROSKeros Therapeutics$15.04+1.1%$15.40$9.12▼$72.37$458.21M0.971.01 million shs703,279 shsTCRXTScan Therapeutics$2.31+0.9%$1.95$1.02▼$6.22$129.95M0.99752,571 shs326,823 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-6.50%-45.69%-45.13%-24.90%-43.90%KALVKalVista Pharmaceuticals+1.18%+0.27%-13.92%-23.66%-7.33%KROSKeros Therapeutics+1.08%+8.75%-4.51%+4.01%-74.06%TCRXTScan Therapeutics+0.87%-6.85%+25.54%+19.69%-54.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$11.22-6.5%$18.72$8.04▼$24.17$325.85M2.391.93 million shs3.86 million shsKALVKalVista Pharmaceuticals$11.13+1.2%$12.84$7.30▼$17.28$555.75M-0.151.27 million shs1.22 million shsKROSKeros Therapeutics$15.04+1.1%$15.40$9.12▼$72.37$458.21M0.971.01 million shs703,279 shsTCRXTScan Therapeutics$2.31+0.9%$1.95$1.02▼$6.22$129.95M0.99752,571 shs326,823 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-6.50%-45.69%-45.13%-24.90%-43.90%KALVKalVista Pharmaceuticals+1.18%+0.27%-13.92%-23.66%-7.33%KROSKeros Therapeutics+1.08%+8.75%-4.51%+4.01%-74.06%TCRXTScan Therapeutics+0.87%-6.85%+25.54%+19.69%-54.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 2.64Moderate Buy$31.71182.66% UpsideKALVKalVista Pharmaceuticals 2.90Moderate Buy$26.43137.45% UpsideKROSKeros Therapeutics 2.40Hold$30.0099.47% UpsideTCRXTScan Therapeutics 2.67Moderate Buy$7.80237.66% UpsideCurrent Analyst Ratings BreakdownLatest TCRX, KROS, ARCT, and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025KALVKalVista PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025KROSKeros TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/25/2025TCRXTScan TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025ARCTArcturus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$60.00 ➝ $12.0010/23/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $20.0010/23/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$49.00 ➝ $12.0010/22/2025ARCTArcturus TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$48.00 ➝ $23.0010/22/2025ARCTArcturus TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral10/20/2025KROSKeros TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.0010/13/2025ARCTArcturus TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$152.31M2.00N/AN/A$8.90 per share1.26KALVKalVista Pharmaceuticals$1.43M394.33N/AN/A$1.92 per share5.80KROSKeros Therapeutics$232.84M1.97N/AN/A$14.11 per share1.07TCRXTScan Therapeutics$2.82M46.49N/AN/A$4.26 per share0.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)KALVKalVista Pharmaceuticals-$183.44M-$3.94N/AN/AN/AN/A-212.79%-97.85%12/4/2025 (Estimated)KROSKeros Therapeutics-$187.35M$0.3148.52N/A1.928.06%2.96%2.74%11/5/2025 (Estimated)TCRXTScan Therapeutics-$127.50M-$1.09N/AN/AN/A-1,964.88%-63.33%-40.19%11/11/2025 (Estimated)Latest TCRX, KROS, ARCT, and KALV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025TCRXTScan Therapeutics-$0.35N/AN/AN/A$1.98 millionN/A11/6/2025Q3 2025ARCTArcturus Therapeutics-$1.09N/AN/AN/A$17.47 millionN/A11/5/2025Q3 2025KROSKeros Therapeutics-$1.11N/AN/AN/A$4.22 millionN/A9/11/2025Q1 2026KALVKalVista Pharmaceuticals-$0.91-$1.12-$0.21-$1.12$1.97 million$1.43 million8/12/2025Q2 2025TCRXTScan Therapeutics-$0.28-$0.2848-$0.0048-$0.28$1.31 million$3.08 million8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/6/2025Q2 2025KROSKeros Therapeutics-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A5.905.90KALVKalVista PharmaceuticalsN/A5.375.37KROSKeros TherapeuticsN/A21.1121.11TCRXTScan Therapeutics0.187.067.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%KALVKalVista PharmaceuticalsN/AKROSKeros Therapeutics71.56%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics16.60%KALVKalVista Pharmaceuticals4.30%KROSKeros Therapeutics20.60%TCRXTScan Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.16 million22.65 millionOptionableKALVKalVista Pharmaceuticals10050.52 million48.35 millionOptionableKROSKeros Therapeutics10030.47 million24.19 millionOptionableTCRXTScan Therapeutics10056.75 million54.28 millionNot OptionableTCRX, KROS, ARCT, and KALV HeadlinesRecent News About These CompaniesTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 17, 2025 | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Recommendation of "Moderate Buy" by AnalystsOctober 17, 2025 | marketbeat.com2 Overlooked Stocks to Snap Up in 2025October 16, 2025 | msn.comWeiss Ratings Reiterates Sell (D-) Rating for TScan Therapeutics (NASDAQ:TCRX)October 9, 2025 | marketbeat.comTScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025September 17, 2025 | globenewswire.comTScan Therapeutics to Participate in Upcoming Investor ConferencesSeptember 3, 2025 | globenewswire.comTScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash WiselyAugust 15, 2025 | finance.yahoo.comTScan Therapeutics Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comTScan Therapeutics reports Q2 EPS (28c), consensus (32c)August 12, 2025 | msn.comTScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue EstimatesAugust 12, 2025 | zacks.comTScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comTScan Therapeutics Elects New Directors at Annual MeetingJuly 27, 2025 | theglobeandmail.comOne TScan Therapeutics Insider Raised Stake By 18% In Previous YearJuly 19, 2025 | finance.yahoo.comTscan Therapeutics Inc News (TCRX) - Investing.comJuly 9, 2025 | investing.comTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comLynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockMay 22, 2025 | insidertrades.comWhat Analysts Are Saying About TScan Therapeutics StockMay 9, 2025 | nasdaq.com3TCRX : What Analysts Are Saying About TScan Therapeutics StockMay 7, 2025 | benzinga.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comTScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comTScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual MeetingApril 30, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCRX, KROS, ARCT, and KALV Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$11.22 -0.78 (-6.50%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$11.25 +0.03 (+0.27%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.KalVista Pharmaceuticals NASDAQ:KALV$11.13 +0.13 (+1.18%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$11.12 -0.01 (-0.09%) As of 10/24/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Keros Therapeutics NASDAQ:KROS$15.04 +0.16 (+1.08%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$15.04 0.00 (0.00%) As of 10/24/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.TScan Therapeutics NASDAQ:TCRX$2.31 +0.02 (+0.87%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.32 +0.01 (+0.43%) As of 10/24/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
